Article Text

other Versions

PDF
Anti-CCP revised criteria for the classification of rheumatoid arthritis
  1. Katherine P Liao (kliao{at}partners.org)
  1. Brigham and Women's Hospital, United States
    1. Kerri L Batra (kbatra{at}partners.org)
    1. Brigham and Women's Hospital, United States
      1. Lori Chibnik (lchibnik{at}rics.bwh.harvard.edu)
      1. Brigham and Women's Hospital, United States
        1. Peter H Schur (pschur{at}partners.org)
        1. Brigham & Women's Hospital-Harvard Med School, United States
          1. Karen H Costenbader (kcostenbader{at}partners.org)
          1. Brigham and Women's Hospital; Assistant Professor of Medicine, Harvard Medical School, United States

            Abstract

            Objective: Classification of rheumatoid arthritis (RA) is increasingly important as new therapies can halt the disease in its early stages. Antibodies to cyclic citrullinated peptides (anti-CCP) are widely used for RA diagnosis, but are not in the 1987 American College of Rheumatology (ACR) Criteria for RA Classification. We developed and tested the performance characteristics of new criteria for RA classification, incorporating anti-CCP.

            Methods: We identified all subjects seen in our Arthritis Center with rheumatoid factor (RF) and anti-CCP tested simultaneously between January 1 and June 30, 2004 and reviewed their medical records for the ACR criteria, rheumatologists’ diagnoses, RF and anti-CCP. We revised the ACR criteria in two ways: (1) adding anti-CCP, (2) replacing rheumatoid nodules and erosions with anti-CCP (CCP 6 criteria). We compared sensitivity and specificity of all criteria, in all subjects and in subjects with arthritis symptoms < 6 months.

            Results: Medical records of 292 subjects were analysed: mean age was 54 years, 82% were women, and mean symptom duration was 4.1 years. 17% were RF+ and 14% were anti-CCP+ at initial testing. 78 (27%) had definite RA per treating rheumatologist at latest follow-up.

            The CCP 6 criteria increased sensitivity for RA classification for all subjects regardless of symptom duration: 74% vs. 51% for ACR criteria with a loss in specificity (81% vs. 91%). Sensitivity was greatly improved in subjects with symptoms < 6 months: 25% vs. 63% for ACR criteria with a decrease in specificity.

            Conclusion: The CCP 6 criteria improved upon the sensitivity of the ACR criteria, most remarkably for subjects with symptoms < 6 months and could be used for classification of subjects for RA in clinical studies.

            • classification
            • cyclic citrullinated peptide
            • early rheumatoid arthritis
            • rheumatoid arthritis

            Statistics from Altmetric.com

            Request permissions

            If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.